Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration

Physics in Medicine and Biology

Volumn 55, Issue 23, 2010, Pages 7037-7054

  Taddei, Phillip J ^a   Chell, Erik ^b   Hansen, Steven ^b   Gertner, Michael ^b   Newhauser, Wayne D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Oraya Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE-RELATED MACULAR DEGENERATION; AZIMUTHAL DIRECTION; CLINICAL TARGET VOLUMES; EXTERNAL BEAM RADIOTHERAPY; FIELD JUNCTIONS; LINEAR DISPLACEMENTS; LOW ENERGIES; LOW-ENERGY X-RAYS; MONTE CARLO SIMULATION; MULTI-MODALITY; NORMAL TISSUE; OPTIC DISC; OPTIC NERVE; ORTHOGONAL DIRECTIONS; RADIATION THERAPY; SETUP ERRORS; STEREOTACTIC RADIOSURGERY; TARGETING ACCURACY; VASCULAR ENDOTHELIAL GROWTH FACTOR;

COMPUTER SIMULATION; DISEASE CONTROL; EYE PROTECTION; HISTOLOGY; MONTE CARLO METHODS; OPHTHALMOLOGY; SENSITIVITY ANALYSIS; WALLS (STRUCTURAL PARTITIONS);

RADIOTHERAPY;

ARTICLE; EYE; FEMALE; HUMAN; MALE; METHODOLOGY; MONTE CARLO METHOD; MOVEMENT (PHYSIOLOGY); ORGANS AT RISK; OSTEOPOROSIS; PATHOPHYSIOLOGY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RADIOSURGERY;

DOSE FRACTIONATION; EYE; FEMALE; HUMANS; MALE; MONTE CARLO METHOD; MOVEMENT; ORGANS AT RISK; OSTEOPOROSIS; RADIATION DOSAGE; RADIOSURGERY;

EID: 78650057294     PISSN: 00319155     EISSN: 13616560     Source Type: Journal    
DOI: 10.1088/0031-9155/55/23/S06     Document Type: Article

References (30)

1. AREDS 2001 A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no 8 Arch. Ophthalmol. 119 1417-36
2. Avila M P, Farah M E, Santos A, Duprat J P, Woodward B W and Nau J 2009a Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration Br. J. Ophthalmol. 93 305-9
3. Avila M P, Farah M E, Santos A, Kapran Z, Duprat J P, Woodward B W and Nau J 2009b Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD Retina 29 157-69
4. Bressler N M, Bressler S B, Congdon N G, Ferris F L III, Friedman D S, Klein R, Lindblad A S, Milton R C and Seddon J M 2003 Potential public health impact of age-related eye disease study results: AREDS report no 11 Arch. Ophthalmol. 121 1621-4
5. Brown M M, Brown G C, Brown H C and Peet J 2008 A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration Ophthalmology 115 1039-45
6. Dobler B and Bendl R 2002 Precise modelling of the eye for proton therapy of intra-ocular tumours Phys. Med. Biol. 47 593-613
7. Finger P T, Chakravarthy U and Augsburger J J 1998 Radiotherapy and the treatment of age-related macular degeneration. External beam radiation therapy is effective in the treatment of age-related macular degeneration Arch. Ophthalmol. 116 1507-11
8. Hanlon J, Lee C, Chell E, Gertner M, Hansen S, Howell R W and Bolch W E 2009 Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose Med. Phys. 36 3671-81
9. Herault J, Iborra N, Serrano B and Chauvel P 2005 Monte Carlo simulation of a proton therapy platform devoted to ocular melanoma Med. Phys. 32 910-9
10. Hermann RM, Praider O, Lauritzen K, Ott M, Schmidberger H and Hess C F 2002 Does escalation of the apical dose change treatment outcome in β-radiation of posterior choroidal melanomas with 106Ru plaques? Int. J. Radiat. Oncol. Biol. Phys. 52 1360-6
11. Jaakkola A, Heikkonen J, Tommila P, Laatikainen L and Immonen I 2005 Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study Ophthalmology 112 567-73 (Pubitemid 41108854)
12. Jager R D, Mieler W F and Miller J W 2008 Age-related macular degeneration N. Engl. J. Med. 358 2606-17
13. Koch N and Newhauser W 2005 Virtual commissioning of a treatment planning system for proton therapy of ocular cancers Radiat. Prot. Dosim. 115 159-63
14. Koch N, Newhauser W D, Titt U, Gombos D, Coombes K and Starkschall G 2008 Monte Carlo calculations and measurements of absorbed dose per monitor unit for the treatment of uveal melanoma with proton therapy Phys. Med. Biol. 53 1581-94
15. Koch N C and Newhauser W D 2010 Development and verification of an analytical algorithm to predict absorbed dose distributions in ocular proton therapy using Monte Carlo simulations Phys. Med. Biol. 55 833-53
16. Lee C, Chell E, Gertner M, Hansen S, Howell R W, Hanlon J and Bolch W E 2008 Dosimetry characterization of a multibeam radiotherapy treatment for age-related macular degeneration Med. Phys. 35 5151-60
17. Ma C M, Coffey C W, DeWerd L A, Liu C, Nath R, Seltzer S M and Seuntjens J P 2001 AAPM protocol for 40-300 kV x-ray beam dosimetry in radiotherapy and radiobiology Med. Phys. 28 868-93
18. Marcus D M, Sheils W, Johnson M H, McIntosh S B, Leibach D B, Maguire A, Alexander J and Samy C N 2001 External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial Arch. Ophthalmol. 119 171-80
19. Missotten L, Dirven W, van der Schueren A, Leys A, De Meester G and van Limbergen E 1998 Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995 Graefes Arch. Clin. Exp. Ophthalmol. 236 164-73
20. 106Rh plaque and proton radiotherapy for ocular melanoma: a comparative dosimetric study Radiat. Prot. Dosim. 116 454-60
21. Moyers M F, Galindo R A, Yonemoto L T, Loredo L, Friedrichsen E J, Kirby M A, Slater J D and Slater J M 1999 Treatment of macular degeneration with proton beams Med. Phys. 26 777-82
22. Newhauser W D, Koch N C, Fontenot J D, Rosenthal S J, S Gombos D, Fitzek M M and Mohan R 2007 Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy Phys. Med. Biol. 52 3979-90
23. Pelowitz D B 2008 MCNPX™ user's manual, version 2.6.0 (Los Alamos, NM: Los Alamos National Laboratory)
24. Rivard M.J 2009 Monte Carlo radiation dose simulations and dosimetric comparison of the model 6711 and 9011 125I brachytherapy sources Med. Phys. 36 486-91
25. Rivard M J, Davis S D, DeWerd L A, Rusch T W and Axelrod S 2006 Calculated and measured brachytherapy dosimetry parameters in water for the Xoft Axxent x-ray source: an electronic brachytherapy source Med. Phys. 33 4020-32
26. Rosenfeld P J, Brown D M, Heier J S, Boyer D S, Kaiser P K, Chung C Y and Kim R Y 2006a Ranibizumab for neovascular age-related macular degeneration N. Engl. J. Med. 355 1419-31
27. Rosenfeld P J, Rich R M and Lalwani G A 2006b Ranibizumab: phase III clinical trial results Ophthalmol. Clin. N. Am. 19 361-72
28. van Ginderdeuren R, van Limbergen E and Spileers W 2005 18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma Br. J. Ophthalmol. 89 1306-10
29. Yonemoto L T, Slater J D, Blacharski P, Archambeau J O, Loredo L N, Oeinck S C, Teichman S,MoyersMand Slater J M 2000 Dose response in the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: results of a phase I/II dose-escalation study using proton radiotherapy J. Radiosurg. 3 47-54
30. Zambarakji H J, Lane A M, Ezra E, Gauthier D, Goitein M, Adams J A, Munzenrider J E, Miller J W and Gragoudas E S 2006 Proton beam irradiation for neovascular age-related macular degeneration Ophthalmology 113 2012-9